Collaboration is the driving force behind accountable care organizations (ACOs), a strategy that requires a partnership among a diverse set of stakeholders?providers, payers and purchasers.
Collaboration is the driving force behind accountable care organizations (ACOs), a strategy that requires a partnership among a diverse set of stakeholders–providers, payers and purchasers.
“ACOs represent a model offering the opportunity for the three constituents to reduce costs and improve quality, a concept that moves away from a fragmented fee–for–service environment and payment for volume of services to one with shared risk and savings and outcomes–based care,” said Bill Shea, partner, Healthcare Business Consulting for Cognizant, one of the panelists at a Thursday session on delivery model transformation.
Although a perspective from another important partner in an ACO-the hospital-was missing from the discussion, Shea said that these providers often serve as key facilitators in developing an ACO and are able to bend the trend through collaboration.
Panelists explored the operational elements of an ACO, including financial, organizational, care management and approaches to information technology.
“We need to develop the appropriate business structure to manage significant risk and align incentives among all parties,” he said. “By doing so, we anticipate a 0% spend trend, which early evidence has supported.”
At the heart of the ACO is the ability to integrate resources and information to provide care across the entire outpatient and inpatient spectrum–supporting outcomes–based payment systems, developing patient registries and master patient indexes and feeding the electronic medical record.
Shea isn’t convinced, however, that ACOs necessarily will hit a home run on their first step up to the plate.
“Information technology and developing the ACO infrastructure might very well stand in the way of the new models,” he said.
Shea also pointed to the challenge of assigning specific populations to ACOs, which can be critical in delivering on managed care concepts that have worked, providing population health and lowering variability of care among providers.
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with Ceci Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
The Departments of Health and Human Services (HHS), Labor, and the Treasury, released final rules on short-term, limited-duration insurance (STLDI) and independent, non-coordinated excepted benefits coverage, addressing issues related to the low-quality insurance, or "junk insurance" plans.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 28th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More